Teva Pharma (TEVA) volatility flat into Mylan (MYL) granted FDA approval of Copaxone

Teva (NYSE: TEVA) October weekly call option implied volatility is at 40, October is at 41, November is at 47; compared to its 52-week range of 24 to 61 into Mylan (Nasdaq: MYL) was granted FDA approval of the first generic for Copaxone.

You May Also Be Interested In

• Alphabet (GOOGL) call put ratio 1.6 calls to 1 put with a focus on June 22 weekly calls as share price down 6%
• AIG (AIG) call put ratio 4 calls to 1 put with a focus on June 26 weekly calls as share price up 3.9%
• Micron Technology (MU) call put ratio 1 calls to 1 put into quarter results